Published in final edited form as:

Crit Care Med. 2015 August ; 43(8): 1785–1786. doi:10.1097/CCM.0000000000001102.

Persistent Acute Kidney Injury

John A. Kellum

The Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, and University of Pittsburgh Medical Center, Pittsburgh, PA

Keywords

acute kidney injury; renal replacement therapy; dialysis; clinical trials; biomarkers; renal recovery; mortality

One of the more challenging aspects for the study and clinical evaluation of acute kidney injury (AKI) is the fact that initially, dysfunction is indistinguishable from a normal decrease in function in response to a number of abnormal clinical states (e.g., hypovolemia, hypotension). Indeed even a normal stress response may result in transient oliguria. The problem for the clinician is to distinguish a physiological reduction in kidney function from a pathological state. Importantly, even when there is no pathology in the kidney per se, this does not necessarily make the condition benign. Analogous to pulseless electrical activity in a patient with a normal myocardium, the loss of function will nevertheless be fatal if not corrected. While a cardiac arrest will be fatal in just a few minutes, “renal arrest” (i.e. anuria) requires days—but the condition is fatal nonetheless. As far back as ancient times, it was appreciated that an “empty bladder” was a fatal disease although it wasn’t until Galen who established the kidneys as the source of the problem (1).

Over the last decade, the definitions and staging criteria for AKI have been standardized (2–4) and operationalized for clinical management (4). They have formed the basis for quality improvement programs (5) and for biomarker development and registration (6, 7).

Importantly, these definitions do not differentiate, in any systematic way, pathologic from “physiologic” decreases in renal function. The reasons for this are partly pragmatic, there are no gold standards for ensuring adequate resuscitation for example, and partly because even mild (8) or transient (9) AKI carries a hazard for long-term outcome.

Staging criteria have also been agnostic to the underlying cause of AKI, assigning a function-based stage without regard to the etiology. This too may be justified by the fact that in critically ill patients, the cause of AKI is usually multifactorial. Traditional approaches to acute alterations in kidney function were developed long before AKI was an established entity and certainly before any standardization in the criteria for diagnosis. These approaches emphasized a quasi-anatomic nomenclature, pre-, intra-, and post-renal as a way

Corresponding Author: John A. Kellum MD, MCCM, Professor of Critical Care Medicine, Medicine, Bioengineering, and Translational & Clinical Science Director, Center for Critical Care Nephrology, 604, Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261., kellumja@upmc.edu, Telephone: 412-647-8110, Fax: 412-647-2645.

Competing Financial Interest: The author discloses no competing financial interests.

of organizing the differential diagnosis. The approach is “quasi-anatomic” because apart from post-renal (i.e. obstructive), the terms do not actually mean very much. For example, “pre-renal” can mean low circulating blood volume and hypovolemic shock but can also mean reduced renal perfusion due to intra-abdominal hypertension. “Intra-renal” might refer to glomerular nephritis but it might also be tubular ischemic injury after aortic cross-clamping in vascular surgery—a decidedly “pre-renal” mechanism. The terms do not guide management either because there is no single therapy for intra-renal AKI and pre-renal AKI might indicate the need for fluid resuscitation (hypovolemic shock) but equally might indicate the need for fluid removal (right ventricular failure). In an age where the term AKI has displaced terms like acute renal failure or acute tubular necrosis and standard criteria have superseded vague clinical constructs, the concepts of “transient” and “persistent” AKI are probably more useful than pre- or intra-renal.

The importance of time as another dimension of AKI along with severity was first observed by Coca et al., who demonstrated that duration of AKI based on creatinine following surgery was independently associated with subsequent outcome (10). Earlier this year, we reported results of an analysis involving more than 32,000 patients admitted to one of 8 ICUs at a single medical center during an 8-year period (July 2000–October 2008) (9). It was clear from our analysis that AKI persistence has a substantial influence on outcome. For example 4 days at stage 3 (by serum creatinine) AKI results in an approximately 30% rate of death or dialysis at 1 year. It requires more than a week at stage 1 to incur the same hazard. Persistence of oliguria is more constrained because after three days almost all patients either resolve, die, receive renal replacement therapy or develop significant azotemia. Nevertheless, even over three days one can observe an effect of duration on outcomes independent of stage (9).

On this backdrop Perinel and colleagues (11) studied 283 patients with AKI admitted to one of four University hospital ICUs in France. They defined *persistent* AKI as absence of recovery within three days and they defined recovery as resolution of oliguria (without diuretics) and return to baseline serum creatinine (or a 50% reduction). 175 (62%) patients had persistent AKI according to these definitions. They did not report on a requirement for recovery to be sustained but otherwise their criteria were reasonably strict and consistent with published recommendations (12). Patients with persistent AKI were more severe and more likely to die prior to hospital discharge (39% vs. 30% for transient AKI). Persistent AKI remained associated with hospital mortality after adjusting for severity of illness (OR 0.58; 95% CI 0.36–0.95). It was no longer significant in a model that included severity of AKI but this was likely a function of the relatively small sample size since other studies have found an independent association between AKI duration and outcome (9, 10).

Interestingly, patients with persistent AKI more frequently exhibited concomitant creatinine elevation and oliguria compared with patients with transient AKI (30.3% vs. 13.0%; $P < 0.0001$) and as per other studies, underscores the importance of urine output measurement in the evaluation of AKI (9, 13).

Based on these observations the authors argue that persistent AKI could be a relevant endpoint for future studies. I would agree with this and argue one step further, that we

should target persistent AKI for clinical management. While AKI that rapidly resolves still has worse outcome compared to patients without AKI, the outcomes are far better compared to persistent AKI. There are a number of things that could be done, both from a diagnostic and management perspective, for these patients. Table 1 provides a list of potential considerations—grouped under the acronym DAMAGE. While these recommendations are derived mainly from clinical experience and common sense, they could serve as a trail to be followed, improved, strengthened and eventually transitioned to a well paved road.

Acknowledgments

This work was supported in part by R01DK083961 from the National Institute of Diabetes, and Digestive, and Kidney Diseases (NIDDK). The content of this paper is solely the responsibility of the author and does not necessarily represent the official views of NIDDK or NIH.

Copyright form disclosures: Dr. Kellum received support for article research from the National Institutes of Health (NIH).

References

1. Diamandopoulos A. Twelve centuries of nephrological writings in the Graeco-Roman world of the Eastern Mediterranean (from Hippocrates to Aetius Amidanus). *Nephrol Dial Transplant*. 1999; 14(Suppl 2):2–9. [PubMed: 10334662]
2. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. 2004;R204–12.
3. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. 2007;R31.
4. KDIGO Acute Kidney Injury Workgroup. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Acute Kidney Injury. *Kidney inter Suppl*. 2012; 2:1–138. 2012; 1–141.
5. Macleod A. NCEPOD report on acute kidney injury-must do better. *Lancet*. 2009; 374:1405–1406. [PubMed: 19854359]
6. Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. *Crit Care*. 2013; 17:R25. [PubMed: 23388612]
7. Bihorac A, Chawla LS, Shaw AD, et al. *Am J Respir Crit Care Med*. 2014; 189:932–939. [PubMed: 24559465]
8. Linder A, Fjell C, Levin A, et al. Small Acute Increases in Serum Creatinine are Associated with Decreased Long Term Survival in the Critically Ill. *Am J Respir Crit Care Med*. 2014
9. Kellum JA, Sileanu FE, Murugan R, et al. Classifying AKI by Urine Output versus Serum Creatinine Level. *J Am Soc Nephrol*. 2015
10. Coca SG, King JT, Rosenthal RA, et al. *Kidney Int*. 2010; 78:926–933. [PubMed: 20686452]
11. Perinel S, Vincent F, Lautrette A, et al. Transient and Persistent Acute Kidney Injury and the Risk of Hospital Mortality in Critically Ill Patients: Results of a Multicenter Cohort Study. *Crit Care Med*. 2015 in press.
12. Kellum JA. How Can We Define Recovery after Acute Kidney Injury? Considerations from Epidemiology and Clinical Trial Design. *Nephron Clin Pract*. 2014; 127:81–88. [PubMed: 25343827]
13. Mandelbaum T, Scott DJ, Lee J, et al. *Crit Care Med*. 2011; 39:2659–2664. [PubMed: 21765352]

Table 1**Kidney DAMAGE—An Approach to Patients with Persistent AKI**

Goal	Recommendations	Comment
Determine Etiology	<ul style="list-style-type: none"> Evaluate for ongoing drivers of injury (e.g. sepsis, drugs) Consider less common causes of AKI (e.g. vasculitis, interstitial nephritis) Consider kidney biopsy Nephrology consultation 	Persistent AKI is more likely to be due to conditions that are less easily reversed (e.g. sepsis) or have not been recognized (e.g. drug-induced, cardiorenal).
Avoid further injury	<ul style="list-style-type: none"> Avoid unnecessary nephrotoxic drug and IV radio-contrast exposure Consider patient location that minimizes risk (e.g. ICU vs. ward) 	New nephrotoxic drug and radio-contrast exposures as well as fluid overload or hemodynamic instability may result further kidney injury
Monitor	<ul style="list-style-type: none"> Serum creatinine (daily) Urine output Consider hemodynamic monitoring 	Monitoring is helpful not only to assess recovery but also fluid balance and in select patients, cardiac function.
Adverse drug events	<ul style="list-style-type: none"> Adjust medication selection and dosing 	Not only are drugs important potential causes of persistent AKI but drugs may need to be changed or dosed differently in these patients
Goals of treatment	<ul style="list-style-type: none"> Assess treatment goals with respect to dialysis and other therapy 	Patients with persistent AKI may ultimately require dialysis or other life support—a reassessment of goals and preferences may be warranted
Ensure follow-up	<ul style="list-style-type: none"> Assess renal function within 30 days Assess cardiovascular risk Monitor/treat hypertension 	Patients with persistent AKI, especially those without recovery at discharge are at high risk for chronic kidney disease, and for cardiovascular events